Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01035723
Other study ID # 999905406
Secondary ID 05-DA-N406
Status Completed
Phase
First received
Last updated
Start date September 13, 2005
Est. completion date February 25, 2013

Study information

Verified date February 25, 2013
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- New research on genetics and the human genome has helped to identify certain genes that affect specific parts of the brain, including the parts that may be involved in drug use and dependency. Researchers are interested in studying both genetic information and brain activity to better understand variations in brain function among individuals.

Objectives:

- To study brain activity in conjunction with specific genetic information provided by healthy volunteers including smokers, non-smokers, people with drug dependence, and those who do not have any dependence on any substance.

Eligibility:

- Healthy volunteers between 18 and 50 years of age.

Design:

- This is an 8 10 hour study which may be completed in 1, 2, or 3 visits.

- Participants will complete questionnaires about emotional and psychological responses to different situations, including stressful situations.

- Participants will have a training session in a mock (fake) scanner to practice tasks to be completed in the real scanner.

- Participants will have the following two types of magnetic resonance imaging (MRI) scans in one scan session of the brain:

- A structural MRI scan to provide basic information about each participant's brain.

- A functional MRI scanning session, in which participants will perform a memory task to provide information about brain activity.

- Participants will provide blood samples for research and testing....


Description:

Objective:

Functional genetic polymorphisms have been identified that influence the morphology and function of brain regions that have been implicated in addictive and neuropsychiatric disorders. This protocol aims to integrate genotyping with both structural and functional brain imaging to investigate the impact of specific functional polymorphisms on morphology and function of the amygdala and the hippocampus and on behavior mediated by these brain regions. Functional polymorphisms of the BDNF, SLC6A4, and DISC1 genes will be studied, as these are logical candidates to influence variability in brain morphology and function. The overall hypothesis is that variation in morphology and function of the amygdala and the hippocampus is explained, at least in part, by specific genotype differences.

Study Population:

The study population will consist of healthy male and female adult volunteers (18-50 years old).

Design:

After being medically cleared and giving written informed consent, each participant will undergo a structural MRI scan of the brain to be used for volumetric measurements of the amygdala, hippocampus, prefrontal cortex, and intracranial cavity. Each participant will undergo an fMRI scanning session, which will include an emotional context memory task specifically designed to require functioning of the amygdala and the hippocampus. A venous blood sample will be collected for genotyping of BDNF, SLC6A4, and DISC1 polymorphisms. Additionally, other functional polymorphisms that may influence brain structure may also be evaluated, in exploratory fashion. If participants have already had a blood sample collected for the genetics portion of another Neuroimaging Research Branch study, they may not need to have another sample taken.

Outcome Measures:

This protocol will provide no direct benefits to research participants. Understanding the relationship between genetic polymorphisms and brain morphology and their association to brain function and behavior may provide further clues to the neurobiological mechanisms underlying addictive and neuropsychiatric disorders. The potential risks are related to acquiring MRI scans in general. Medical supervision will be provided throughout the study.


Recruitment information / eligibility

Status Completed
Enrollment 221
Est. completion date February 25, 2013
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility - INCLUSION CRITERIA:

To be eligible for this study, subjects must:

1. Be between the ages of 18 and 50.

2. Be in good health.

3. Be right handed.

4. Individuals with a substance abuse disorder may be included.

EXCLUSION CRITERIA:

Subjects will be excluded if they:

1. Are not suitable to undergo an MRI experiment due to pregnancy, implanted metallic devices (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts), body morphology, or claustrophobia.

2. Have coagulopathies, history of or current superficial or deep vein thrombosis, musculoskeletal abnormalities restricting an individual s ability to lie flat for an extended period of time.

3. Have HIV or syphilis.

4. Have a neurological illness to include, but not limited to, seizure disorders, migraine, multiple sclerosis, movement disorders, or history of head trauma, CVA, CNS tumor.

5. Have any current AXIS I psychiatric disorders including Attention Deficit Disorder (ADD). Have regular use of any prescription, over-the-counter, or herbal medication that may alter CNS function, cardiovascular function or neuronal-vascular coupling.

6. Have current dependence on any substance other than cocaine, marijuana, or nicotine.

7. Are cognitively impaired or are learning disabled.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institute on Drug Abuse Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Austin CP, Ma L, Ky B, Morris JA, Shughrue PJ. DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. Neuroreport. 2003 May 23;14(7):951-4. — View Citation

Bartzokis G, Altshuler LL, Greider T, Curran J, Keen B, Dixon WJ. Reliability of medial temporal lobe volume measurements using reformatted 3D images. Psychiatry Res. 1998 Apr 10;82(1):11-24. — View Citation

Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, Stokes J, Handelsman L, Medrano M, Desmond D, Zule W. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003 Feb;27(2):169-90. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To understand the relationship between genetic polymorphisms and brain morphology and their association to brain function and behavior.
See also
  Status Clinical Trial Phase
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT02375516 - Preventing Drug Abuse Among Hispanic Adolescents N/A
Withdrawn NCT01275391 - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use Phase 1/Phase 2
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Completed NCT00907309 - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use Phase 1/Phase 2
Completed NCT02228044 - Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment N/A
Withdrawn NCT01427465 - Brief Integrative Alcohol Interventions for Adolescents N/A
Completed NCT00350909 - Brief Intervention for Drug Abusing Adolescents Phase 2
Completed NCT00148031 - Improving Hepatitis C Treatment in Injection Drug Users Phase 4
Completed NCT00383838 - Self-Selected Brief Alcohol Intervention for Adolescents N/A
Completed NCT00722644 - Cognitive Behavioral Stress Management for HIV+ Drug Abusers Phase 1
Completed NCT00451854 - Student Athlete Testing Using Random Notification N/A
Completed NCT01036711 - Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI
Terminated NCT02741076 - Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain Phase 4
Completed NCT06044363 - Satir Model for Self-esteem, Mental Health, and Family Function Among Individuals With Substance Use Disorders N/A
Recruiting NCT05037487 - Evaluation of Smoked THC and CBD in Men and Women Phase 1
Recruiting NCT04725266 - A Family-based Intervention for Drug-abusing Adults in Hong Kong N/A
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A
Completed NCT04105621 - Westlake Personalized Nutrition and Health Cohort for Drug Addicts